ArticleAnti-cancer agents in medicinal chemistry2015
Using cytochalasins to improve current chemotherapeutic approaches.
Article in Anti-cancer agents in medicinal chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Cytochalasins are a fascinating class of natural compounds: advances in the chemistry, biological activities, mode of action, and structure-activity relationships of novel cytochalasins isolated in the last decade are described.Natural products and bioprospecting · 2026Review
- Mechano-regulation of cancer cell memory in tumor progression and therapy.Mechanobiology in medicine · 2026Review
- NQO1-Responsive Prodrug for in Cellulo Release of Cytochalasin B as Cancer Cell-Targeted Migrastatic.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Xylariaides A and B, novel cytochalasans with a unique 5/6/5/3 ring system from a soil fungus Xylaria sp. Y01.Natural products and bioprospecting · 2025Article
- Comprehensive Cell Biological Investigation of Cytochalasin B Derivatives with Distinct Activities on the Actin Network.Journal of natural products · 2024Article
- A Multi-Omics Analysis of an Exhausted T Cells' Molecular Signature in Pan-Cancer.Journal of personalized medicine · 2024Article
- Endophytic fungi: A future prospect for breast cancer therapeutics and drug development.Heliyon · 2024Review
- Sustained activation of the FGF1-MEK-ERK pathway inhibits proliferation, invasion and migration and enhances radiosensitivity in mouse angiosarcoma cells.Journal of radiation research · 2024Article
- Review
- Article
- A Comparison of Cellular Uptake Mechanisms, Delivery Efficacy, and Intracellular Fate between Liposomes and Extracellular Vesicles.Advanced healthcare materials · 2023Review
- The Potential for Targeting AVIL and Other Actin-Binding Proteins in Rhabdomyosarcoma.International journal of molecular sciences · 2023Article
- Characteristics and Cytotoxic Effects of Nano-Liposomal Paclitaxel on Gastric Cancer Cells.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Cytochalasans and Their Impact on Actin Filament Remodeling.Biomolecules · 2023Review
- Cytochalasin B Influences Cytoskeletal Organization and Osteogenic Potential of Human Wharton's Jelly Mesenchymal Stem Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Role of motor proteins in human cancers.Saudi journal of biological sciences · 2022Review
- Role of actin cytoskeleton in cargo delivery mediated by vertically aligned silicon nanotubes.Journal of nanobiotechnology · 2022Article
- Cytochalasin B Modulates Nanomechanical Patterning and Fate in Human Adipose-Derived Stem Cells.Cells · 2022Article
- The Role of Cytoskeletal Proteins in the Formation of a Functional In Vitro Blood-Brain Barrier Model.International journal of molecular sciences · 2022Article
- Genomic Characterization ofJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the amount of progress cancer therapy has made in recent years is commendable, considerable limitations still remain. Most agents preferentially target rapidly proliferating cells, thereby destroying tumorigenic growths. Unfortunately, there are many labile cells in the patient that are also rapidly dividing, ultimately perpetuating significant side effects, including immunosuppression. Cytochalasins are microfilament-directed agents most commonly known for their use in basic research to understand cytoskeletal mechanisms. However, such agents also exhibit profound anticancer activity, as indicated by numerous in vitro and in vivo studies. Cytochalasins appear to preferentially damage malignant cells, as shown by their minimal effects on normal epithelial and immune cells. Further, cytochalasins influence the end stages of mitosis, suggesting that such agents could be combined with microtubule-directed agents to elicit a profound synergistic effect on malignant cells. Therefore, it is likely that cytochalasins could be used to supplement current chemotherapeutic measures to improve efficacy rates, as well as decrease the prevalence of drug resistance in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.